In Brief
The paracaspase Malt1 is a key regulator of antigen receptor signaling and frequently mutated in human lymphoma.
Gewies et al. demonstrate that the proteolytic function of Malt1 is largely dispensable for lymphocyte activation but critical for regulatory T cell (Treg) and innate-like B cell development and protection from IFNg-mediated autoinflammation in vivo.
SUMMARY
The paracaspase Malt1 is a central regulator of antigen receptor signaling that is frequently mutated in human lymphoma. As a scaffold, it assembles protein complexes for NF-kB activation, and its proteolytic domain cleaves negative NF-kB regulators for signal enforcement. Still, the physiological functions of Malt1-protease are unknown. We demonstrate that targeted Malt1-paracaspase inactivation induces a lethal inflammatory syndrome with lymphocyte-dependent neurodegeneration in vivo. Paracaspase activity is essential for regulatory T cell (Treg) and innate-like B cell development, but it is largely dispensable for overcoming Malt1-dependent thresholds for lymphocyte activation. In addition to NF-kB inhibitors, Malt1 cleaves an entire set of mRNA stability regulators, including Roquin-1, Roquin-2, and Regnase-1, and paracaspase inactivation results in excessive interferon gamma (IFNg) production by effector lymphocytes that drive pathology. Together, our results reveal distinct threshold and modulatory functions of Malt1 that differentially control lymphocyte differentiation and activation pathways and demonstrate that selective paracaspase blockage skews systemic immunity toward destructive autoinflammation.
INTRODUCTION
Signals from antigen receptors (AgRs) control the development and activation of T and B lymphocytes during adaptive immunity. These pathways are essential for host defense against infections but can lead to immunodeficiency, autoimmunity, or cancer when dysregulated. The pathway that activates NF-kB transcription factors through the Card11, Bcl10, and Malt1 (CBM) protein complex is a key regulator of lymphocyte signaling for T and B cell differentiation and activation (Thome et al., 2010) . Genetic deletion of any of these factors results in severe deficits in the development of regulatory T cells (Tregs), innate-like B1 B cells, and marginal zone B cells (Newton and Dixit, 2003; Ruefli-Brasse et al., 2003; Ruland et al., 2001 Ruland et al., , 2003 . Moreover, although the differentiation of conventional T and B cells is largely intact in the absence of Card11/Bcl10/Malt1 signaling, all three factors are essential for productive lymphocyte activation. Consequently, loss-of-function mutations within the CBM complex result in severe combined immunodeficiencies in humans and in mice (Greil et al., 2013; Jabara et al., 2013; McKinnon et al., 2014; Newton and Dixit, 2003; Ruefli-Brasse et al., 2003; Ruland et al., 2001 Ruland et al., , 2003 . On the other hand, gain-of-function alterations of CBM signaling are recurrently detected in human non-Hodgkin lymphoma, where they trigger constitutive NF-kB activation, which is required for tumor cell survival (Staudt, 2010) . These genomic aberrations include various independent chromosomal translocations involving Bcl10 or Malt1 and oncogenic mutations within Card11 in mucosa-associated lymphoid tissue (MALT) lymphoma and in diffuse large B cell lymphoma (Akagi et al., 1999; Lenz et al., 2008; Streubel et al., 2003; Willis et al., 1999) .
Malt1 is the essential effector molecule within the CBM complex. This protein contains an amino-terminal death domain and immunoglobulin-like domains for protein-protein interactions and a proteolytically active paracaspase domain that shares homology with caspases and metacaspases. In resting lymphocytes, Malt1 is preassociated with Bcl10, and these two molecules coassociate with Card11 upon signal induction after T cell receptor (TCR) engagement or B cell receptor ligation (Thome et al., 2010) . Malt1 acts as a scaffold, recruiting protein E3 ubiquitin ligases such as Traf6 to the newly formed CBM signalosome. This association leads to the nondegrading ubiquitination of Bcl10, Traf6, and Malt1 itself and thereby activates IkB kinase (IKK), which in turn promotes canonical NF-kB signaling by phosphorylating inhibitory IkB proteins, thereby inducing their degradation (Dü wel et al., 2010) . Malt1 further activates the JNK and p38 kinases (Ruland et al., 2003) , which regulate transcription factors such as ATF2 (Gozdecka and Breitwieser, 2012) . The proteolytic domain of Malt1, which has not been well defined at the physiological level, can cleave the A20 and CYLD deubiquitinases that target K63-type polyubiquitin chains, and it can negatively regulate NF-kB (Coornaert et al., 2008; Staal et al., 2011) . In addition, Malt1 cleaves the NF-kB family member RelB, which also acts as an inhibitor of the canonical NF-kB pathway in T cells (Hailfinger et al., 2011) . Moreover, Malt1 has recently been shown to cleave the endoribonuclease Regnase-1 (Uehata et al., 2013) , which regulates the stability of mRNAs.
Because Malt1 has nonredundant activating roles in AgR signaling and possesses the only enzymatic activity within the CBM complex, extensive pharmaceutical efforts to develop Malt1 protease inhibitors for the treatment of prevalent chronic and malignant immune-mediated diseases are being pursued (Fontá n and Melnick, 2013; Vucic and Dixit, 2009 ). Indeed, selective inhibition of MALT1 protease activity via peptide or smallmolecule inhibitors is selectively toxic to human lymphoma cell lines that exhibit aberrant CBM activity (Ferch et al., 2009; Nagel et al., 2012) . Moreover, because Malt1-deficient mice are protected from autoimmune diseases such as experimental autoimmune encephalomyelitis (Brü stle et al., 2012) , it has been speculated that pharmaceutical agents that block Malt1 paracaspase activity could inhibit chronic inflammatory reactions in autoimmunity and would thus have the potential for use as anti-inflammatory immunosuppressors. Despite these endeavors, the physiological functions of Malt1 paracaspase activity and the differential roles of the Malt1 scaffold versus its proteolytic activity in lymphocyte development, activation, and immune homeostasis are unknown.
We report here that animals with a targeted Malt1 protease inactivation develop fatal inflammation with neurodegeneration. Although the paracaspase activity of Malt1 is largely dispensable for overcoming the Malt1-controlled threshold for lymphocyte activation, this activity is essential for the differentiation of lymphocytes including Tregs, marginal zone B cells, and B1 B cells. In activated conventional T cells, Malt1 cleaves, in parallel with NF-kB inhibitors, an entire set of mRNA stability factors that includes Roquin-1 and Roquin-2 in addition to Regnase-1. Also, Malt1 proteolytic inactivation results in excessive interferon gamma (IFNg) production that mediates inflammatory pathology. Our data demonstrate differential regulation of lymphocyte differentiation and activation pathways by Malt1 and reveal that Malt1 protease inhibition results in spontaneous lethal autoinflammation.
RESULTS

Systemic Inflammation in the Absence of Malt1 Paracaspase Activity
To selectively inactivate Malt1 enzymatic activity in vivo, we replaced the active site cysteine within its protease domain with alanine (C472A; Figures S1A and S1B Figure 1A ). To assay catalytic activity, we stimulated splenocytes with phorbol 12-myristate 13-acetate and ionomycin (PMA/Iono). Signal-induced cleavage of the Malt1 substrate Ac-LRSR-AMC (Nagel et al., 2012) was detected in activated splenocytes from Malt1 +/À mice, but not in those from Malt1 À/À or in Malt1 PM/À animals ( Figure 1B ).
Thus, although the paracaspase mutant Malt1 protein was expressed normally, it did not have proteolytic function. Although Malt1 À/À mice are immunodeficient, the absence of Malt1 does not affect animal growth or viability under homeostatic conditions, and Malt1 À/À mice reach a normal age without overt pathology (Ruefli-Brasse et al., 2003; Ruland et al., 2003) . In sharp contrast, the Malt1 PM/À paracaspase mutant mice failed to thrive and started to develop severe cachexia (Figure 1C) and lymphadenopathy with a strong increase in the numbers of T and B cells ( Figure 1D ). Malt1 PM/À mice developed a systemic inflammatory disorder characterized by highly elevated serum concentrations of the inflammatory cytokines IFNg and tumor necrosis factor (TNF) already at an age of 6 to 10 weeks ( Figure 1E ), whereas serum cytokine levels of interleukin 1b (IL-1b), IL-17, and IL-6 were not substantially elevated in Malt1 PM/À mice ( Figure S2A Figure 1F ) with locally increased inflammatory cytokine expression ( Figure 1G ). In vitro colon cultures also showed spontaneous production of high IFNg, TNF, and IL-1b levels in Malt1
, samples ( Figure 1H ). In a model of inflammatory bowel disease, we treated the animals with 3.5% dextran sodium sulfate (DSS) for 5 days to trigger intestinal epithelial damage (Oh et al., 2014) . Malt1 PM/À mice developed a more rapid and aggravated inflammatory disease compared to control mice, with severe hemorrhagic diarrhea, increased weight loss ( Figure 1I ), and an elevated histological severity score ( Figures 1J and 1K ). Starting from 3 months of age, all Malt1 PM/À mutant mice suffered from a spontaneous neurological disorder with dystonia and progressive ataxia (Figures 2A and 2B ), indicative of a cerebellar defect. Rotarod analysis was used to quantitatively characterize this motor-coordination deficit (Shiotsuki et al., 2010) . Whereas Malt1 +/À and Malt1 À/À mice stayed on the rotating rod for a minimum of 120 s, the Malt1 PM/À animals failed to accomplish this task even after numerous trials ( Figure 2C ; see also Figure 2H ). Loss of Purkinje cells is associated with severe ataxic syndromes (Kullmann et al., 2012) . Histopathological analysis of the CNS indeed showed a marked reduction of Purkinje cells in the cerebellar cortex of Malt1 PM/À mice ( Figure 2D ). Notably, we also observed elevated numbers of CD4 + and CD8 + T lymphocytes in the brains of Malt1 PM/À mice compared to control animals ( Figure 2E ). To determine the role of lymphocytes in the systemic inflammation and neurodegeneration, we crossed Malt1 PM/À mice to Rag1-deficient animals, which lack T and B cells. Moreover, we wanted to test whether disease in the paracaspase mutants is caused by aberrant Malt1 signaling from within canonical Bcl10/Malt1 complexes or whether the catalytically inactive Malt1 protein mediates its pathological effects via Bcl10-independent mechanisms. Thus, we also crossed the Malt1 PM allele into a Bcl10-deficient background. The absence of Bcl10 prevented both systemic inflammation and ataxia (Figures 2F and 2G) , and the lack of lymphocytes in the Rag1
background also completely rescued Malt1 PM/À mice from disease, normalized the levels of inflammatory cytokines in the blood ( Figure 2F ), and prevented the development of neurological defects as determined by clinical ataxia scoring ( Figure 2G ) and rotarod analysis ( Figure 2H ). Altogether, these in vivo observations reveal a counterintuitive autoinflammatory condition and neuropathology upon selective Malt1 paracaspase inactivation. Moreover, the results indicate that these disorders are caused by aberrant Malt1 function within Bcl10-containing complexes, and they prove genetically that the pathology in Malt1 paracaspase mutant mice is dependent on aberrant lymphocyte activity.
Differential Control of Lymphocyte Differentiation and Activation Signals
Because of the findings above, we next studied lymphocyte differentiation and activation in Malt1 Compared to the wild-type, both Malt1 PM/À and Malt1 À/À CD4 + T cells showed slightly reduced viability after 2 days of stimulation in vitro ( Figure 4B ). However, whereas the surviving Malt1
T cells exhibited severely impaired TCR-induced proliferation as expected (Ruefli-Brasse et al., 2003; Ruland et al., 2003) , Malt1 PM/À T cells divided vigorously, although their proliferation rate was suboptimal when compared to Malt1 +/À T cells (Figure 4C) . Moreover, in contrast to the complete Malt1 deletion, paracaspase inactivation failed to affect the upregulation of the activation marker CD25 ( Figure 4D ). Next, we immunized the animals with (4-hydroxy-3-nitrophenyl)acetyl-ovalbumin (NP-OVA) to study antigen-specific lymphocyte activation in vivo. Again, as expected, the T celldependent production of NP-specific immunoglobulin G1 (IgG1) antibodies was defective in Malt1 À/À mice ( Figure 4E ) mice (n = 9) after NP-OVA immunization measured by NP-specific ELISA. Sera were collected at the indicated time points after immunization. The data are shown in a logarithmic scale with horizontal bars indicating the means (two-tailed unpaired t test). All analyses were performed with animals at 8 to 10 weeks of age. *p < 0.05; ns, not significant. (Ruefli-Brasse et al., 2003; Ruland et al., 2003) . However, Malt1 PM/À mice produced normal amounts of antigenspecific IgG1 2 weeks after immunization, although their adaptive immune response was delayed (Figure 4E) . Together, these data demonstrate that the paracaspase activity of Malt1 is, to a considerable extent, dispensable for Malt1-controlled lymphocyte activation pathways in vitro and in vivo.
Threshold and Modulatory Activity of Malt1 in TCR Signaling
We next isolated naive CD4 + T cells for biochemical analysis. As previously shown, Malt1 ablation blocks PMA/Iono-induced and anti-CD3/anti-CD28-induced IKK activation ( Figures 5A and 5D) , and the MAP kinases p38 and Jnk were also not activated in Malt1
À/À T cells despite normal Erk signaling ( Figure 5B ) (Ruefli-Brasse et al., 2003; Ruland et al., 2003) . In contrast, the selective paracaspase mutation did not impair IKK, p38, or Jnk activation ( Figures 5A and 5B ). Consistently, IkBa was phosphorylated and degraded normally ( Figures 5A and 5D) , and the transcription factor Atf2 was also phosphorylated normally in Malt1 PM/À T cells, but not in Malt1-deficient T cells ( Figure 5C ).
Next, we investigated the cleavage of candidate Malt1 substrates in primary Malt1
PM/À T cells stimulated with anti-CD3/ anti-CD28 or with PMA/Iono. Robust signal-induced proteolysis of RelB and Cyld was observed in T cells from Malt1 +/À mice, but not in T cells from Malt1 À/À or Malt1 PM/À mice ( Figures 5E  and S3A ). Due to the lack of an antibody that recognizes cleaved murine A20, we were unable to study endogenous A20 processing. Because these Malt1 targets can negatively regulate canonical NF-kB activity (Hailfinger et al., 2011; Reiley et al., 2007) , we measured NF-kB DNA binding 8 hr after T cell stimulation. Electromobility shift assays revealed suboptimal NF-kB DNA binding in Malt1 PM/À T cells ( Figure 5F ). In line with the defective cleavage of RelB ( Figure 5E ), stimulated T cells from Malt1 PM/À mice showed increased amounts of nuclear RelB DNA-binding compared to Malt1 +/À T cells ( Figure 5G ). Moreover, the DNAbinding activities of c-Rel and p50 were significantly reduced in Malt1 PM/À mice, whereas p65 DNA binding was not affected by mutation of the paracaspase ( Figure 5G ). Thus, the paracaspase activity of Malt1 fine-tunes canonical NF-kB activity after initial IKK activation and particularly controls the full nuclear DNA binding of the NF-kB subunits p50 and c-Rel. Immune-modulatory gene expression is not only controlled by transcription factors but also strongly regulated at the level of mRNA stability ( , and Malt1 À/À mice were stimulated with plate-bound anti-CD3 (5 mg/ml) and soluble anti-CD28 (2 mg/ml) for the indicated time points in the presence of the proteasome inhibitor MG132 (10 mg/ml). Cell lysates were analyzed by immunoblot using antibodies specific for RelB, Cyld, and b-actin.
(F) CD4 + T cells were left unstimulated or were stimulated for 8 hr by plate-bound anti-CD3 and anti-CD28. The DNA binding activity of the nuclear extracts was analyzed by an electrophoretic mobility shift assay using oligos with NF-kB binding sites or NF-Y binding sites as a control. (G) Naive CD4 + T cells were treated as in (F). Nuclear extracts were prepared and DNA binding activities of specific NF-kB subunits were quantified by an ELISA-based assay. For each subunit, the data from three experiments were normalized to Malt1 +/À control T cells and are expressed as the mean ± SEM (two-tailed unpaired t test).
(H) CD4 + T cells from Malt1
, and Malt1 À/À mice were stimulated as in (E). Cell lysates were analyzed by immunoblot using antibodies specific for Malt1, Roquin1/2, Regnase1, and Gapdh. All analyses were performed with animals at 8 to 10 weeks of age. *p < 0.05.
Cell Reports 9, 1292-1305, November 20, 2014 ª2014 The Authors 1299 , and Malt1 À/À mice (n = 4 each) were left unstimulated or were stimulated for 4 hr with anti-CD3 and anti-CD28. Total RNA was isolated, and gene expression profiling was performed. The microarray data were analyzed for the expression of NF-kB target genes that were >2-fold upregulated upon TCR stimulation in at least one of the three genotypes. The upregulated genes could be classified into four
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Regnase-1 was recently identified as a Malt1 substrate that controls mRNA stability (Uehata et al., 2013) , and we discovered independently that Malt1 can cleave the RNA-binding proteins Roquin-1 and Roquin-2 (Jeltsch et al., 2014) . Similar to Regnase-1, the Roquin paralogs bind to stem-loop structures in the 3 0 UTRs of target mRNAs to control their decay (Leppek et al., 2013) . To define the requirement for Malt1 proteolysis of Regnase-1 and Roquin degradation, we performed western blots using either an anti-Regnase-1 antibody or a monoclonal antibody that recognizes a conserved N-terminal epitope in Roquin-1 and Roquin-2 using lysates from activated T cells. The Roquin proteins were completely degraded in stimulated wild-type T cells, and the proteolysis of the Roquins was strictly dependent on Malt1 proteolytic activity ( Figures 5H and S3B) . Moreover, Regnase-1 cleavage was observed in wild-type T cells but was abolished in Malt1 PM/À T cells, similar to the results in Malt1 À/À T cells ( Figures 5H and S3C ).
Malt1 Protease Activity Prevents Pathological Overproduction of IFNg
The simultaneous functions of Malt1-mediated proteolysis in signal-dependent NF-kB control and the cleavage of mRNA decay factors prompted us to investigate the overall impact of the paracaspase mutation on TCR-induced mRNA expression.
To this end, we fluorescence-activated cell sorting (FACS)-purified naive (CD4
, and Malt1 À/À mice, stimulated these cells via the TCR, and performed microarray mRNA expression analysis. First, we focused on NF-kB target mRNAs (as defined in the Supplemental Experimental Procedures) that were at least 2-fold upregulated in at least one of the three genotypes. Statistical criteria subdivided these mRNAs into qualitatively distinct groups ( Figure 6A ). The first group includes mRNAs such as the c-Rel target Bcl2l1 that were robustly upregulated in Malt1 Figure 6A ).
Because we initially observed that Malt1 PM/À animals develop spontaneous systemic inflammation with pathological IFNg levels in vivo, we investigated IFNg production after T cell activation in more detail. Increased IFNg mRNA levels were confirmed by RT-PCR analysis in stimulated PM/À mice, we crossed the Malt1 PM allele into an IFNg-deficient background. Intriguingly, whereas nine out of ten Malt1 PM/À littermates in an IFNg +/+ or IFNg +/À background had to be euthanized within 20 weeks of birth because they developed the neuropathology described above, the absence of IFNg rescued the Malt1 PM/À mice from neuropathology ( Figure 6F ), although lymphadenopathy was still present in these animals ( Figure 6G ). IFNg À/À animals also failed to develop cachexia ( Figure 6I ).
Moreover, the inflammatory activity in the gastric mucosa in Malt1
PM/À ;IFNg À/À mice was also significantly reduced compared to that in Malt1 PM/À mice ( Figure 6J ). Together, these data demonstrate that IFNg is a key driver of the systemic inflammatory disorder in paracaspase mutant mice.
DISCUSSION
Together, our genetic results identify distinct molecular and cellular functions of Malt1 that act in concert to maintain tissue homeostasis. Together with previously published work, we propose the following model: the Malt1 scaffold sets a threshold for antigen receptor signaling to activate IKK, Jnk, and p38 for proinflammatory gene transcription. The proteolytic activity of Malt1 has a subsequent dual modulatory role: it degrades a series of negative NF-kB regulators to enforce transcription of a subset of immune response genes, and it inactivates an entire class of mRNA-binding proteins that directly control mRNA decay. Thus, both transcriptional activity and mRNA stability, which in combination are highly important for the balanced expression of immune regulatory factors (Ivanov and Anderson, 2013; Villarino et al., 2011) , are intimately controlled by the Malt1 protease. These mechanisms differentially control lymphocyte differentiation and activation.
Comparable to a complete Malt1 deletion, the selective inactivation of Malt1 proteolytic activity prevents the development of anti-inflammatory thymus-derived Tregs and of marginal zone and B1 B cells. Although mRNA stability pathways can contribute to developmental lymphocyte fate decisions, the development of these specific T-and B cell lineages is particularly sensitive to perturbations in NF-kB activity (Gerondakis and Siebenlist, 2010) . In particular, c-Rel activity is required for regulatory T cell lineage commitment (Ruan et al., 2009) . Because the Malt1 protease mediates full NF-kB and c-Rel activation, we hypothesize that such signals are important for the differentiation and/or maintenance of Tregs, marginal zone and B1 B cells.
In contrast to its vital function in lymphocyte development, the paracaspase activity of Malt1 is to a considerable extent dispensable for its mediation of lymphocyte activation. In vitro, T cell signaling induces normal IKK, Jnk, and p38 activation as well as p65 DNA binding and Atf2 phosphorylation, and activated Malt1 PM/À T cells expand almost as robustly as wild-type T cells.
In vivo, the pure Malt1 scaffold is also sufficient to overcome the threshold for productive lymphocyte activation, as demonstrated by the ability of Malt1 PM/À mice to mount robust adaptive immune responses after T cell-dependent antigen challenge in contrast to Malt1 À/À animals. However, without Malt1-dependent proteolysis, lymphocyte activity is not appropriately counterbalanced. This can in part be explained by the developmental defects in the Treg lineage, because Tregs are required to prevent lethal multiorgan autoimmune inflammation. Such pathologies occur in the IPEX syndrome, which is caused by a naturally occurring Foxp3 mutation in humans resulting in Treg deficiencies, as well as upon targeted Foxp3 gene inactivation or after toxin-mediated depletion of Tregs in mice (Bacchetta et al., 2006; Kim et al., 2007) . Thus, insufficient Treg-dependent suppression of Malt1 PM/À effector T cells likely supports the pathological accumulation of lymphocytes in paracaspase mutant mice that infiltrate mucosal tissue and drive lethal autoimmune inflammation. Intriguingly, we also observed lymphocyte-dependent degeneration of Purkinje cells in paracaspase mutant mice resulting in a severe cerebellar ataxic syndrome. Although the exact pathomechanism that provokes this neurodegenerative disease remains to be determined, the disorder shares histopathological characteristics with paraneoplastic cerebellar degeneration in human Hodgkin and non-Hodgkin lymphoma, wherein a loss of Purkinje cells is also mediated by aberrant lymphocyte activity (Briani et al., 2011; Darnell, 2004) . The inability of lymphocytes that completely lack Malt1 to overcome the initial threshold for activation can explain why these immunemediated pathologies are observed in Malt1 PM/À mice, but not in Malt1 À/À mice.
After activation of conventional T cells, Malt1 not only regulates the NF-kB pathway but also cleaves Roquin-1, Roquin-2, and Regnase-1, which fine-tune the expression of a vast set of target mRNAs, particularly ones that have highly dynamic expression that needs to be altered rapidly during immune responses (Akira, 2013; Jeltsch et al., 2014) , and during helper T cell differentiation, Roquin and Regnase-1 cooperate in the repression of shared target mRNAs (Jeltsch et al., 2014) . Conditional gene targeting of the individual factors in T cells has shown that Roquin-1, Roquin-2, and Regnase-1 are all required for the maintenance of immune homeostasis (Uehata et al., 2013; Vogel et al., 2013) . Transgenic T cell-specific overexpression of Roquin-1 has also been linked to inflammatory responses via enhanced production of IFNg and other inflammatory cytokines Kim et al., 2012) . Germline mutations in Roquin-1 that generate hypomorphic Roquin-1 (san) alleles also induce an accumulation of pathological effector T cells with excessive production of IFNg due to a breakdown in IFNg mRNA repression Lee et al., 2012; Vinuesa et al., 2005) . Thus, nonphysiological levels and activity of Roquin proteins have previously been associated with exacerbated IFNg production, although the exact molecular mechanisms for this effect have remained unclear. Roquin-1, Roquin-2, and Regnase-1 bind to stem loop motifs of multiple target mRNAs (Akira, 2013) , and bioinformatic analysis has estimated that more than 50% of the total transcriptomic changes that are detected during T cell activation are directly regulated at the level of mRNA stability (Cheadle et al., 2005) . In addition, Regnase-1 controls gene transcription by directly counteracting the endonuclease Dicer during pre-microRNA processing (Suzuki et al., 2011) , and Roquins can also function as degradative ubiquitin ligases for signaling proteins under certain conditions (Maruyama et al., 2014) . Thus, in activated Malt1 PM/À T cells, multiple factors that are primarily controlled by NF-kB, Regnase-1, and Roquin-1 and Roquin-2 are dysregulated and additional genes are assumed to be up-or downregulated secondarily to the primary factors. We observed that the stability of the Regnase-1 and Roquin targets IL-2 and Ox40, but not that of Icos or c-Rel, is diminished in Malt1 PM/À T cells (data not shown) (Uehata et al., 2013; Vogel et al., 2013) . This overall complexity indicates that more than a single linear pathway is likely responsible for the initiation and perpetuation of the pathological activities of Malt1 PM/À lymphocytes, and future studies are required to dissect these pathways. Nevertheless, as the final consequence of paracaspase inhibition, we detected excessive IFNg generation in vivo, and the ability of an IFNg À/À background to rescue paracaspase mutant animals from cachexia and neurodegeneration established excessive IFNg production as a mechanism of the pathology. Malt1 was originally identified from a chromosomal translocation breakpoint in MALT lymphoma (Dierlamm et al., 1999) . Intensive research over more than a decade has identified Malt1 as a major activator of adaptive immunity that can drive normal and malignant lymphocyte proliferation and survival. The overarching paradigm presumes that Malt1 paracaspase inhibition would be immunosuppressive. We report here that Malt1 not only induces and amplifies immune-activating signals but also antagonizes inflammation through its proteolytic activity, which controls regulatory T cell development and intrinsic effector cell pathways of transcription and posttranscriptional regulation. Thus, the distinct threshold and modulatory functions within Malt1 balance pro-and anti-inflammatory immunity. The net outcome of selective paracaspase inactivation in vivo is an imbalance of the immune system that results in lethal lymphocyte-and IFNgmediated inflammation. These surprising results cast some concern on the idea of chronically and systemically inhibiting Malt1 proteolytic activity for therapeutic purposes in humans.
EXPERIMENTAL PROCEDURES Ethics Statement
All animal work was conducted in accordance with German Federal Animal Protection Laws and approved by the Institutional Animal Care and Use Committee at the Technical University of Munich.
Malt1 Paracaspase Enzymatic Assay
Lymphocytes were isolated from spleen and lymph nodes, and 8 3 10 7 cells
were left unstimulated or were stimulated for 30 min at 37 C with 200 nM PMA plus 500 nM ionomycin. The assay was performed as described previously (Nagel et al., 2012) .
Serum Cytokine Detection ELISA was performed using the Mouse IFNg OptEIA Kit (#555138, BD Biosciences). For detection of serum cytokine concentrations, the Enhanced Sensitivity CBA kit (BD Biosciences) was applied for the respective cytokines.
Neurophenotyping
Ataxia was scored according to a composite phenotyping system including hindlimb clasping, ledge test, gait, and kyphosis as described previously (Guyenet et al., 2010) . For rotarod analysis, the mice were tested in ten consecutive trials with 60 s intertrial intervals at constant speed (25 rpm) for a maximum of 120 s per trial on a mouse rotarod (Ugo Basile).
Purification and Stimulation of T Cells
Total T cells were purified by negative selection using magnetic beads (Dynal, Invitrogen) against B cells (B220) and myeloid cells (CD11b). CD4 + T cells were purified using MACS CD4 + or CD4 + CD62L + T Cell isolation kits (Miltenyi). For cleavage experiments, cells were pretreated with 10 mg/ml MG132 for 20 min at 37 C in medium. Cells were stimulated with PMA (100 nM, Adipogen) and ionomycin (250 nM, Alexis) or with plate-bound anti-CD3 (50 or 5,000 ng/ml, 145-2C11) and anti-CD28 (2 mg/ml, 37.51, both from eBioscience) antibodies after precoating with anti-Syrian hamster antibodies (10 mg/ml, F[ab 0 ]2 fragment of IgG H + L, rabbit, Jackson ImmunoResearch) in RPMI 1640 medium supplemented with 5% fetal bovine serum (v/v), penicillin (100 U/ml)/streptomycin (100 mg/ml), L-glutamine (2 mM), and 2-mercaptoethanol (50 mM, all Gibco) for the indicated time points at 37 C.
Statistics
Statistical analysis was performed using GraphPad Prism (GraphPad Software) and Microsoft Excel. In general, groups were compared using unpaired two-tailed t tests assuming normal distributions and unequal variances or unpaired two-tailed Mann-Whitney tests as indicated in the figure legends.
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